抑制剂治疗:艺术的状态。

文章的细节

引用

复制到剪贴板

夏皮罗一个

抑制剂治疗:艺术的状态。

Semin内科杂志。2001年10月,38(4 5 12):保险。

PubMed ID

11735107 (在PubMed

]

文摘

嗜血抑制剂的患者的治疗提出了许多挑战。重组激活因子VII (rFVIIa;NovoSeven,诺和诺德公司、丹麦哥本哈根)是一种新的治疗选择患者人群。优化给药方案可以通过考虑(1)个人药物动力学(尤其是在儿科人口);(2)高剂量丸方案;(3)连续输注(CI)包括大剂量CI;(4)早期治疗过程中NovoSeven流血事件;(5)利用NovoSeven作为预防性治疗。综述了文献涉及这些问题。机构的早期治疗已被证明会降低总NovoSeven需求,同时增加疗效。 Pediatric patients may require a higher dose of NovoSeven due to the higher clearance rate and shorter half-life demonstrated by this population. Therefore, the patient's age and/or individual pharmacokinetics and clearance rate should be considered when calculating doses and CI rates. High-dose NovoSeven has been shown to be effective in some patient populations without increased reported adverse events. Despite its short half-life, prophylactic use of NovoSeven has been reported in a small number of patients, with an apparent decrease in bleeding episodes experienced. There has been significant interest in administration of NovoSeven by CI, particularly in patients requiring prolonged treatment, and it has been shown to be successful, although the optimal target factor VII activity has yet to be established and some authors have recommended the use of concomitant antifibrinolytics.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
凝血因子VIIa重组人类	凝血因子VII	蛋白质	人类	未知的	不可用	细节